These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Pearls from the Third Israeli Conference on FMF, other autoinflammatory disorders and AA amyloidosis. Livneh A; Ben-Zvi I Isr Med Assoc J; 2014 May; 16(5):269-70. PubMed ID: 24979827 [No Abstract] [Full Text] [Related]
25. Kidney Transplant in a Patient With Tumor Necrosis Factor Receptor-1 Syndrome (TRAPS): Case Report and Review of the Literature. Rodziewicz N; Bhushan S; Avasia A; Singh N Transplant Proc; 2016; 48(1):265-6. PubMed ID: 26915881 [TBL] [Abstract][Full Text] [Related]
26. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Brau-Javier CN; Gonzales-Chavez J; Toro JR Arch Dermatol; 2012 Mar; 148(3):301-4. PubMed ID: 22431772 [No Abstract] [Full Text] [Related]
27. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Quillinan N; Mannion G; Mohammad A; Coughlan R; Dickie LJ; McDermott MF; McGonagle D Ann Rheum Dis; 2011 Sep; 70(9):1692-3. PubMed ID: 21378401 [No Abstract] [Full Text] [Related]
29. A Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with Tocilizumab. Hosoya T; Mizoguchi F; Hasegawa H; Miura K; Koike R; Kubota T; Miyasaka N; Kohsaka H Intern Med; 2015; 54(16):2069-72. PubMed ID: 26278305 [TBL] [Abstract][Full Text] [Related]
30. Controlling inflammation: contemporary treatments for autoinflammatory diseases and syndromes. Sterba G; Sterba Y Dermatol Clin; 2013 Jul; 31(3):507-11. PubMed ID: 23827252 [TBL] [Abstract][Full Text] [Related]
31. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Rossi-Semerano L; Piram M; Chiaverini C; De Ricaud D; Smahi A; Koné-Paut I Pediatrics; 2013 Oct; 132(4):e1043-7. PubMed ID: 24019411 [TBL] [Abstract][Full Text] [Related]
32. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Cantarini L; Rigante D; Lucherini OM; Cimaz R; Laghi Pasini F; Baldari CT; Benucci M; Simonini G; Di Sabatino V; Brizi MG; Galeazzi M Int J Immunopathol Pharmacol; 2010; 23(3):701-7. PubMed ID: 20943039 [TBL] [Abstract][Full Text] [Related]
33. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Stankovic Stojanovic K; Delmas Y; Torres PU; Peltier J; Pelle G; Jéru I; Colombat M; Grateau G Nephrol Dial Transplant; 2012 May; 27(5):1898-901. PubMed ID: 21931121 [TBL] [Abstract][Full Text] [Related]
35. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. de Koning HD; Schalkwijk J; van der Meer JW; Simon A J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363 [No Abstract] [Full Text] [Related]